Transforming Neurodegenerative Disease Research Through AI

New York is making major strides in biomedical innovation with the official launch of the first research projects powered by its Empire AI supercomputer. Governor Kathy Hochul announced that teams from the University at Albany (UAlbany) and the University of Rochester will be the inaugural users of this cutting-edge AI computing infrastructure. Their collaborative work will focus on developing advanced analytical and therapeutic techniques for neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), myotonic dystrophy, and spinocerebellar ataxias.

This initiative comes as part of New York’s wider mission to establish itself as a national leader in AI-driven research, bolstered by $500 million in public and private funding and a coalition of 10 prominent universities and research institutions. The Empire AI consortium, which includes major state and Ivy League universities as well as advanced research centers, aims to foster innovation for the public good, with current investments concentrating on health, infrastructure, and emerging technologies.

AI Supercomputing Powerhouse Backed by Major Investment

The Empire AI supercomputer, housed at the University at Buffalo, represents one of the largest and most ambitious state-funded AI initiatives in the United States. The platform unites resources across the State University of New York (SUNY) system—including UAlbany, Binghamton University, Stony Brook University, and others—as well as partners from Columbia, Cornell, NYU, and research-focused institutions like the Flatiron Institute and the Icahn School of Medicine at Mount Sinai.

Governor Hochul’s office reported that recently secured funds will further expand researcher access and technological capabilities, enabling unprecedented collaborative potential. By integrating AI supercomputing into academic research, New York seeks to accelerate scientific discovery, attract global research talent, and empower the next generation of bioinformatics and AI experts.

Groundbreaking AI-Driven Biomedical Projects

The inaugural projects leverage advanced computer vision and AI analytics to analyze complex movement patterns in patients with neuromuscular disorders. At the heart of this research is the UAlbany RNA Institute, a well-regarded hub for RNA biology and drug discovery that secured $15.8 million in external grants in 2024 alone. By employing AI to parse vast datasets—capturing high-resolution video and genetic information from patients—the teams hope to identify new biomarkers and potential therapeutic targets much faster than traditional research approaches allow.

According to the Muscular Dystrophy Association and the National Institutes of Health, neurodegenerative diseases like ALS and myotonic dystrophy affect tens of thousands of Americans each year. These conditions are notorious for their complexity and slow progress in the development of effective treatments. The collaboration between UAlbany’s researchers and the University of Rochester—the latter home to the state’s Center of Excellence in Data Science & AI—seeks to harness the power of Empire AI to accelerate drug discovery and improve outcomes for patients with these devastating disorders.

Funding, Partnerships, and Statewide Collaboration

The projects are funded via a multi-pronged approach: $230,000 in matching grants from the Muscular Dystrophy Association and upwards of $2 million in federal grants from the National Institutes of Health and the U.S. Department of Defense. This public and private backing, coupled with New York’s own investment, underscores the critical role of government and nonprofit partnership in driving medical advancement.

On the announcement of the projects, Hope Knight, President and CEO of Empire State Development, remarked, “Artificial intelligence is one of the most powerful tools we have to drive economic development and tackle society’s most complex challenges. By investing in cutting-edge technologies like the Empire AI supercomputer and supporting research institutions across New York, we are not only fostering innovation and job growth but also empowering scientists, educators, and entrepreneurs to improve lives.”

Key academic and industry partners now include the original seven Empire AI members (SUNY, CUNY, Columbia, Cornell, NYU, RPI, Flatiron Institute) with new additions such as the University of Rochester, Rochester Institute of Technology, and Mount Sinai. This network is anticipated to expand further, creating a robust state-wide AI ecosystem.

Educating Tomorrow’s AI Leaders

AI’s growing role in biotech is prompting SUNY’s RNA Institute to broaden its educational reach. During a recent launch event, SUNY Chancellor John B. King Jr. highlighted the significance of placing supercomputing power into the hands of students and researchers. Undergraduate and high school students from across the country participated in presentations demonstrating how AI-driven techniques are already transforming research directions and inspiring new generations to pursue innovation and scientific excellence.

Programs like the Chancellor’s Summer Research Program and the RNA Institute High School Bioinformatics Summer Camp are fostering a diverse pipeline of talent, ensuring New Yorkers are at the forefront of the next wave of biotechnology and AI advances. Notably, these efforts address both the state’s research workforce needs and the broader imperative to democratize AI research and education.

Industry Impact and Future Prospects

The stakes for the application of AI in biomedical research are enormous. According to BIO (Biotechnology Innovation Organization), global investment in AI-powered drug discovery is expected to surpass $25 billion by 2026. States like New York—with deep academic, financial, and healthcare sectors—are uniquely positioned to become leaders in this industry. AI’s strengths in predicting molecular interactions and sifting through terabytes of data drastically reduce the traditional trial-and-error time for drug discovery and treatment optimization.

Experts believe that as AI and supercomputing capacities continue to grow, more breakthrough therapies for neurodegenerative and other complex diseases will emerge. Importantly, partnerships like those surrounding Empire AI ensure these benefits accrue not just to major corporations, but to public health initiatives, underserved patient groups, and the wider community.

About the Key Institutions

• University at Albany RNA Institute: Since its founding in 2010, it has been a leader in RNA-centric research with state-of-the-art facilities, significant grant funding, and a mission to bridge academia, industry, and public health improvements through science and workforce training.
• University of Rochester: Recognized for interdisciplinary AI and RNA research, it houses centers dedicated to both data science innovation and RNA biology, anchoring New York’s biomedical research landscape.
• State University of New York (SUNY) System: The largest comprehensive higher education system in the country, SUNY oversees nearly a quarter of all academic research in New York State and continually invests in technological infrastructure and workforce development.